Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain
Prospective Observational Study on Overall Survival and Quality of Life in Patients Older Than 60 Years With Acute Myeloid Leukemia Diagnosis in Spain, Treated According to Standard Clinical Practice
Prospective, multicenter, observational, national study (EPA-SP) that aims to describe the survival and the quality of life, the clinical management strategies and the prognostic factors for survival related to the patient, in a prospective cohort of patients over 60 with AML diagnosis in Spain and treated outside of clinical trials; that is, under conditions of standard clinical practice.
The study will last 24 months in total from the inclusion of the first patient until the end of the last patient's follow-up
調査の概要
状態
条件
詳細な説明
Following the baseline enrolment visit, the following data corresponding to the patient's visits scheduled according to routine clinical practice will be collected in accordance with the following model:
- Recruitment period: One year of recruitment period, data collection at the baseline visit, every 3 months in one year (month 3, 6, 9 and 12).
- Follow-up period: data collection at the baseline visit, every 3 months in one year (month 3, 6, 9 and 12).
The patient clinical history and the study´s questionnaires will be the source documents. The study will be carried out in the facilities of the Hematology and Hemotherapy Services of the participating centers, collecting the conditions of medical action according to the standard clinical practice.
Being an observational study, no intervention out of standard clinical practice will be performed. No additional diagnostic or treatment procedures will be applied for the patients.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Madrid、スペイン、28040
- Fundacion Jimenez Diaz
-
Madrid、スペイン、28006
- Hospital Universitario La Princesa
-
Madrid、スペイン、28034
- Hospital Universitario Ramón y Cajal
-
Madrid、スペイン、28040
- Hospital Clinico San Carlos
-
Madrid、スペイン、28041
- Hospital Universitario 12 de Octubre
-
Madrid、スペイン、28046
- Hospital Universitario La Paz
-
Madrid、スペイン、28222
- Hospital de Fuenlabrada
-
Madrid、スペイン、28905
- Hospital de Getafe
-
-
Andalucía
-
Córdoba、Andalucía、スペイン、14004
- Hospital Univ. Reina Sofia
-
Sevilla、Andalucía、スペイン、41009
- Hospital Universitario Virgen Macarena
-
-
Andalucía/Cádiz
-
Jerez、Andalucía/Cádiz、スペイン、11404
- Hospital de Jeréz
-
-
Andalucía/Granada
-
Granada、Andalucía/Granada、スペイン、18014
- Hospital Virgen de las Nieves
-
-
Andalucía/Málaga
-
Málaga、Andalucía/Málaga、スペイン、29010
- Hospital Carlos Haya
-
-
Andalucía/Sevilla
-
Sevilla、Andalucía/Sevilla、スペイン、41013
- Hospital Virgen Del Rocio
-
Sevilla、Andalucía/Sevilla、スペイン、41014
- Hospital Universitario Nuestra Señora de Valme
-
-
Aragón
-
Zaragoza、Aragón、スペイン、50009
- Hospital Clinico Lozano Blesa
-
-
Asturias
-
Gijón、Asturias、スペイン、33394
- Hospital Universitario Cabueñes
-
Oviedo、Asturias、スペイン、33011
- Hospital Universitario Central de Asturias
-
-
Baleares
-
Palma de Mallorca、Baleares、スペイン、07120
- Hospital Son Espases
-
-
Castilla-León
-
Burgos、Castilla-León、スペイン、09006
- Hospital Universitario de Burgos
-
León、Castilla-León、スペイン、24071
- Hospital de León
-
Salamanca、Castilla-León、スペイン、37120
- Complejo Hospitalario de Salamanca
-
Valladolid、Castilla-León、スペイン、47003
- Clinico de Valladolid
-
-
Cataluña
-
Barcelona、Cataluña、スペイン、08003
- Hospital del Mar
-
Lleida、Cataluña、スペイン、25198
- Hospital Arnau de Vilanova Lleida
-
Manresa, Barcelona、Cataluña、スペイン、08243
- Hospital de Althaia (H. Sant Juan de Deu de Manresa)
-
-
Comunidad Madrid
-
Madrid、Comunidad Madrid、スペイン、28031
- Hospital Infanta Leonor
-
-
Comunidad Valenciana
-
Alicante、Comunidad Valenciana、スペイン、03010
- Hospital General Alicante
-
Valencia、Comunidad Valenciana、スペイン、46014
- Hospital General Universitario de Valencia
-
-
Extremadura
-
Badajoz、Extremadura、スペイン、06080
- Hospital Infanta Cristina
-
-
Galicia
-
La Coruña、Galicia、スペイン、15006
- Complejo Hospitalario Universitario de A Coruna
-
Ourense、Galicia、スペイン、32005
- Complejo Hospitalario Universitario de Orense
-
-
Islas Canarias
-
Las Palmas de Gran Canaria、Islas Canarias、スペイン、35010
- Hospital Dr. Negrín
-
Santa Cruz de Tenerife、Islas Canarias、スペイン、38010
- Hospital Nuestra Senora de Candelaria
-
Santa Cruz de Tenerife、Islas Canarias、スペイン、38320
- Hospital Universitario Canarias
-
-
Murcia
-
Cartagena, Murcia、Murcia、スペイン、30202
- Hospital Santa Lucía
-
-
Navarra
-
Pamplona, Navarra、Navarra、スペイン、31008
- Complejo Hospitalario de Navarra
-
-
País Vasco
-
Bilbao, Vizcaya、País Vasco、スペイン、48013
- Hospital De Basurto
-
San Sebastián, Guipúzcoa、País Vasco、スペイン、20014
- Hospital Universitario de Donostia
-
Vitoria、País Vasco、スペイン、01009
- Hospital de Txagorritxu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population will consist of approximately 150 patients over 60 with AML diagnosis, defined according to World Health Organization (WHO) 2016 criteria (presence of blasts in the bone marrow or peripheral blood equal to or greater than 20%).
Due to the observational and descriptive nature of the present investigation, the inclusion of a control group is not considered.
説明
Inclusion Criteria:
- Patient of both sexes, aged 65 years and older.
- Any race, nationality or socioeconomic status.
- AML (defined according to WHO 2016 criteria de novo, with previous hematological history or secondary.
- Diagnosis date later than 1st November 2017 and later than each center activation date.
- Patients on first line treatment with any therapeutic strategy (intensive, attenuated or palliative).
- Having given informed consent prior to start the data collection.
Exclusion Criteria:
- Inability to understand the informed consent form.
- AML previously treated (with or without HSCT).
- Acute promyelocytic leukemia.
- Participation in a clinical trial that includes first-line treatment for AML.
- Do not grant consent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Patients diagnosed with AML
The study population will consist of approximately 150 patients over 60 with AML diagnosis according to WHO 2016 criteria.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
The median survival time in adult patients over 60 with AML diagnosis
時間枠:Up to approximately 12 months
|
The overall survival will be calculated, defined as the time from the diagnosis date to the death date from any reason.
In patients who have not died (censored) at the time of data collection, it will be considered the available time to the last control (or last date).
The overall survival will be analyzed using the Kaplan-Meier method, providing the median at 95% CI.
Patients who undergo a hematopoietic transplant will be censored at that time.
|
Up to approximately 12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Overall Survival
時間枠:Up to approximately 12 months
|
The Kaplan Meier curve, with the median and the lower and upper limits of the 95% confidence interval, will be reported.
|
Up to approximately 12 months
|
To describe the socio-demographic and clinical characteristics of patients
時間枠:Up to approximately 12 months
|
A description of the study socio-demographic and clinical variables will be made.
The distributions of absolute and relative frequencies of the qualitative variables will be reported, as well as the measures of central and dispersion tendency of the quantitative variables.
A 95% CIs will be obtained for the main variables.
|
Up to approximately 12 months
|
To describe the disease characteristics
時間枠:Up to approximately 12 months
|
A description of the variables that characterize the disease under study will be made.
The distributions of absolute and relative frequencies of the qualitative variables will be reported, as the measures of central tendency and dispersion of the quantitative variables.
A 95% CIs will be obtained for the main variables.
|
Up to approximately 12 months
|
To describe the front-line treatment strategies
時間枠:Up to approximately 12 months
|
The frequency distributions for the first lines of treatment will be presented, as well as the rate distribution of the most frequent treatment sequences and their evolution.
It will be reported the descriptive statistics period of the first treatment lines.
|
Up to approximately 12 months
|
To assess the HRQOL evolution over time
時間枠:Up to approximately 12 months
|
Descriptive statistics will be reported for each of the five dimensions at every period of application of the EQ-5D, so as an overall lineal model of repeated measures for the VAS.
|
Up to approximately 12 months
|
To evaluate the impact on early mortality
時間枠:Up to approximately 8 weeks
|
The t-test will be used to evaluate the impact of the initial leukocyte count on early mortality (dichotomous variable minus death or not in the first 8 weeks).
The stratified analysis with the same approach will be done for treatments that achieve a sufficient sample.
|
Up to approximately 8 weeks
|
To evaluate the prognostic impact on overall survival
時間枠:Up to approximately 12 months
|
A Cox regression model will be made considering the patient survival as a dependent variable and as possible factors the subjective variables (asthenia and HRQOL) at the time of diagnosis, the patient's general condition, and any other clinical variable that is evaluated as possible predictor.
No more than 10 independent variables will be included in the model for theoretical reasons.
|
Up to approximately 12 months
|
To explore the scales scores to be used as potential predictors tools of treatment tolerability in patients with newly diagnosed AML.
時間枠:Up to approximately 12 months
|
The therapeutic approach will be collected according to the investigator clinical judgment, the score of each of the items on the Lee and GAH scales and the treatment administered tolerability assessment according to the score obtained in each scale.
The weighting coefficients will be calculated using a complete multiple linear regression model and a multiple logistic regression.
The optimal cut points for use as a predictive tool for treatment tolerability will be determined by using the ROC curve technique.
|
Up to approximately 12 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Montserrat Rafel, RML Advocacy、Celgene
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NDS-AML-001
- U1111-1207-6661 (レジストリ識別子:UTN)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。